对炎症性风湿病患者进行多病共存系统筛查可增强预防性用药并减少住院:一项暴露-非暴露研究
该研究基于法国国家健康数据库,将参加多病共存筛查项目的炎症性风湿病患者与对照匹配,评估筛查对预防性用药和住院率的影响。倾向评分匹配后,暴露组主要终点达标率显著高于对照组,且急诊入院及骨折、心血管事件或感染住院显著更少。
要点
- 暴露组主要终点(预防性药物发放)达标率54.8%,对照组44.5%,OR=1.5,p=0.015。
- 暴露组急诊入院及骨折、心血管事件或感染住院发生率7.1%,对照组15.3%,OR=0.42,p<0.01。
- 暴露组严重感染发生率0.7%,对照组3.9%,p=0.03。
核心结论
- 对炎症性风湿病患者进行多病共存系统筛查可增强预防性用药使用并减少住院入院,作者认为这证明为筛查分配时间和资源是合理的。
研究设计与样本
- 研究基于法国国家健康数据库,识别参加筛查项目的炎症性风湿病患者作为暴露组,并与对照匹配。
- 分析包括多因素分析(286例暴露患者和858例对照)和倾向评分匹配分析(281例暴露患者和281例对照)。
- 主要终点为指数日期后一年内评估多病共存预防性药物(包括疫苗、降脂药、抗骨质疏松药和抗血小板药)发放的综合评分。
主要发现
- 倾向评分匹配后,暴露组主要终点达标率54.8%,对照组44.5%,OR=1.5,p=0.015。
- 暴露组疫苗、降胆固醇药物和抗骨质疏松药物使用增加。
- 暴露组急诊入院及骨折、心血管事件或感染住院发生率7.1%,对照组15.3%,OR=0.42,p<0.01。
- 暴露组严重感染发生率0.7%,对照组3.9%,p=0.03。
关键数值与推荐
- 主要终点为指数日期后一年内多病共存预防性药物(疫苗、降脂药、抗骨质疏松药、抗血小板药)发放的综合评分。
- 倾向评分匹配后主要终点达标率:暴露组54.8% vs 对照组44.5%,OR=1.5,p=0.015。
- 急诊入院及骨折、心血管事件或感染住院发生率:暴露组7.1% vs 对照组15.3%,OR=0.42,p<0.01。
- 严重感染发生率:暴露组0.7% vs 对照组3.9%,p=0.03。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONAL: Studies are needed to determine if multimorbidity screening and management reduce the rate of multimorbidity accumulation in patients with chronic inflammatory rheumatic diseases (IRD). OBJECTIVES: This study evaluates the impact of systematic screening programme on patient care and hospitalisation rates. METHODS: Patients with IRD who participated in the screening programme (exposed patients) were identified within the French national health database and matched with controls. Two sets of analysis were performed: one with multivariate analysis and a second using a propensity score matching to ensure comparability between exposed patients and controls. The primary endpoint (PE) was a composite score assessing the dispensation of multimorbidity-preventing drugs, including vaccines, lipid-lowering agents, antiosteoporotic medications and antiplatelet drugs, during the year following the index date. RESULTS: The first analysis included 286 exposed patients and 858 controls, demonstrating a higher rate of meeting the PE in exposed patients (adjusted OR=1.6 (1.2-2.2), p<0.01). Propensity score matching resulted in 281 exposed patients and 281 controls. Exposed patients exhibited a significantly higher rate of meeting the PE compared with controls (54.8% vs 44.5%; OR=1.5; p=0.015), with increased utilisation of vaccines, cholesterol-lowering drugs and antiosteoporotic medications. Furthermore, emergency admission and hospitalisations for fracture, cardiovascular events or infection were significantly less frequent in the exposed group (7.1% vs 15.3%; OR=0.42, p<0.01), with a reduction in severe infections (0.7% vs 3.9%; p=0.03). CONCLUSION: Systematic multimorbidity screening in patients with IRD boosted preventive medication use and reduced hospital admissions, justifying time and resource allocation for screening.
引用
- Immediato Daien C, Georgescu V, Decarriere G, et al. Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study. RMD Open. 2024. PMID: 39357925. doi:10.1136/rmdopen-2024-004490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。